Aeon Global Health (OTCMKTS:AGHC) and Laboratory Corp. of America (NYSE:LH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.
This is a summary of current recommendations and price targets for Aeon Global Health and Laboratory Corp. of America, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aeon Global Health||0||0||1||0||3.00|
|Laboratory Corp. of America||1||7||8||0||2.44|
Laboratory Corp. of America has a consensus price target of $178.29, indicating a potential upside of 35.15%. Given Laboratory Corp. of America’s higher probable upside, analysts plainly believe Laboratory Corp. of America is more favorable than Aeon Global Health.
Insider and Institutional Ownership
90.9% of Laboratory Corp. of America shares are held by institutional investors. 11.5% of Aeon Global Health shares are held by insiders. Comparatively, 0.7% of Laboratory Corp. of America shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Aeon Global Health and Laboratory Corp. of America’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aeon Global Health||-43.06%||-337.28%||-61.42%|
|Laboratory Corp. of America||13.27%||17.13%||7.23%|
Earnings and Valuation
This table compares Aeon Global Health and Laboratory Corp. of America’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aeon Global Health||$16.30 million||0.19||-$8.00 million||($1.15)||-0.37|
|Laboratory Corp. of America||$10.44 billion||1.27||$1.27 billion||$9.60||13.74|
Laboratory Corp. of America has higher revenue and earnings than Aeon Global Health. Aeon Global Health is trading at a lower price-to-earnings ratio than Laboratory Corp. of America, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Aeon Global Health has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Laboratory Corp. of America has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.
Laboratory Corp. of America beats Aeon Global Health on 12 of the 14 factors compared between the two stocks.
About Aeon Global Health
Aeon Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through Laboratory Testing Services and Web-Based Software segments. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, as well as compliance with regulatory requirements. In addition, AEON Global Health Corp. offers post contract customer support services. The company was formerly known as Authentidate Holding Corp. and changed its name to Aeon Global Health Corp. in January 2018. Aeon Global Health Corp. is headquartered in Gainesville, Georgia.
About Laboratory Corp. of America
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests, as well as with Baptist Health. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Receive News & Ratings for Aeon Global Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeon Global Health and related companies with MarketBeat.com's FREE daily email newsletter.